At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 340 enrolled
Drug / intervention
AZD9150 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.
In Brief
A Phase 2 clinical trial evaluating AZD9150, MEDI4736, and 2 other interventions for Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck. Completed, enrolled 340 participants across 44 sites in 6 countries.
Detailed Summary
This multicentre, open-label, Phase 1b/2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Germany, Italy, Spain, United Kingdom, United States
CollaboratorsMedImmune LLC
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartAug 2015
Primary CompletionFeb 2020
Study CompletionOct 2025
TodayJul 2026
First PostedJul 16, 2015
Enrollment StartAug 6, 2015
Primary CompletionFeb 28, 2020
Study CompletionOct 8, 2025
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 11.0 years ago
Interventions
AZD9150drug
AZD9150
MEDI4736drug
MEDI4736
AZD5069drug
AZD5069
tremelimumab (treme)drug
tremelimumab